Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Outpatient Study Investigating Non-prescription Treatments for COVID-19
NCT04621149 · Profact, Inc. · PHASE2 · terminated · last registry update 2022-09-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to recruit participants due to decline in COVID-19.” | – | Registry record, Profact, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-07-28Phase 3 first posted: University of Miami, Acetaminophen + Celebrex (NCT05965492)
- 2023-07-14Phase 3 first posted: Emory University, Cetirizine + Famotidine (NCT05946551)
- 2023-06-22Results posted on the registry: Emory University, Baby aspirin + Tylenol/Acetaminophen (NCT04766996)
- 2023-06-22Also stopped (terminated): Emory University, Baby aspirin + Tylenol/Acetaminophen (NCT04766996)
- 2023-05-30Results posted on the registry: Sanofi, Isatuximab SAR650984 + Acetaminophen (paracetamol) or equivalent (NCT04294459)
- 2023-03-03Results posted on the registry: Hvidovre University Hospital, a drug against HRH2 (NCT04585022)
- 2023-03-03Also stopped (terminated): Hvidovre University Hospital, a drug against HRH2 (NCT04585022)
- 2023-01-06Phase 3 first posted: Beijing Biostar Pharmaceuticals Co., Ltd., Utidelone Injection + Docetaxel Injection (NCT05673590)
- 2022-12-20Results posted on the registry: Mayo Clinic, Famotidine + Loratadine (NCT04248712)
- 2022-12-20Also stopped (terminated): Mayo Clinic, Famotidine + Loratadine (NCT04248712)
- 2022-07-12Results posted on the registry: Genzyme, a Sanofi Company, Alemtuzumab GZ402673 + Glatiramer acetate (NCT03368664)
- 2022-04-26Results posted on the registry: Universitas Indonesia, a drug against HRH2 (NCT04279925)
- 2022-04-26Also stopped (terminated): Universitas Indonesia, a drug against HRH2 (NCT04279925)
- 2022-04-14Also stopped (withdrawn): Hospital for Special Surgery, New York, a drug against HRH2 (NCT03021083)
- 2022-03-21Also stopped (terminated): Sanofi, Isatuximab SAR650984 + dexamethasone (NCT02999633)
- 2022-03-04Results posted on the registry: GlaxoSmithKline, Gepotidacin + Cimetidine (NCT04493931)
- 2022-02-18Results posted on the registry: Prisma Health-Upstate, Famotidine + N-Acetyl cysteine (NCT04545008)
- 2022-02-18Also stopped (terminated): Prisma Health-Upstate, Famotidine + N-Acetyl cysteine (NCT04545008)
- 2021-12-20Phase 3 first posted: Umeå University, antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus). + antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet). (NCT05164081)
- 2021-12-20Also stopped (withdrawn): drpykessupplements.com, Famotidine 20 milligram tablet (NCT04565392)
- 2021-10-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Famotidine 400 mg/50 mL (NCT05084521)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision